| Bioactivity | IRF5-IN-1 (compound C5) is an IRF5 pathway-specific inhibitor. IRF5-IN-1 significantly reduces IRF5 nuclear translocation without affecting the activation of NF-κB p65. IRF5-IN-1 acts through SLC15A4 to selectively inhibit TLR7/8-induced IRF5 responses in cells[1]. |
| Name | IRF5-IN-1 |
| CAS | 689270-18-6 |
| Formula | C27H33N3O2 |
| Molar Mass | 431.57 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Andras Boeszoermenyi, et al. A conformation-locking inhibitor of SLC15A4 with TASL proteostatic anti-inflammatory activity. Nat Commun. 2023 Oct 20;14(1):6626. |
IRF5-IN-1
CAS: 689270-18-6 F: C27H33N3O2 W: 431.57
IRF5-IN-1 (compound C5) is an IRF5 pathway-specific inhibitor. IRF5-IN-1 significantly reduces IRF5 nuclear translocatio
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.